|
|
|
Special Resources
|
The Healthlinks Forum's
The Healthlink's Forum's area has been redesigned and updated with new software and we
invite you to visit, join or look around. The Healthlink's Forum area is
designed to provide you with a blog-like capability allowing you to communicate
with other visitors and healthcare professionals on a variety of healthcare
topics. Here you may ask questions on specific healthcare issues, learn
about new treatments or discuss your own healthcare problems.
|
Healthlinks.net Directory
The Healthlink's Directory
consists of 45 major categories and thousands of subcategories specific to healthcare. At the present time the directory
contains over 216,000 unique links and continues to expand on a daily basis.
Each link has been reviewed and approved by Healthlinks.net before inclusion into the
Healthlink's directory |
Clinical Trials
Healthlinks.net in association with CenterWatch, provides one of the most comprehensive lists of clinical trials and FDA drug approvals on the Internet.
|
Information Services
Our subscription mailing lists provide you with information on healthcare subjects from many of the leading experts. Over 100 categories are available to choose from including: Allergies, Depression, Diabetes, Hair Loss, Heartburn, High Cholesterol, Sexual Health and Weight Loss. New mailing lists are being added on a frequent basis. Subscriptions are free and you may remove yourself at any time.
|
Professional Articles & Resources
Current articles, news and references for the healthcare professional including physicians, nurses and pharmacists. Topics cover the latest in clinical issues, medical & pharmaceutical news and practice management
Go to the Resource >>
View all topics >>
|
| Feature Article: |
 |
Dalbavancin: A novel long-acting lipoglycopeptide antibiotic
Dalbavancin is a new lipoglycopeptide antibiotic in phase 3
trials for the treatment of resistant gram-positive pathogens
including methicillin-resistant Staphylococcus aureus (MRSA)
and vancomycin-resistant enterococci (VRE). This agent exerts
its bactericidal activity by binding to the terminal D-alanyl-D-alanine
moiety of peptidoglycan precursors, thus blocking enzymes
involved in the final stages of peptidoglycan synthesis and cell
wall formation. |
|
MORE >> |
|
|
|
Visit our
Multimedia Center for
audio - video articles on cutting-edge issues. New
articles are added on a daily basis. Also visit our additional
links page from
Healthology |
 Look for this
symbol of professional-level healthcare resources. It signifies that the Web site you are visiting
was reviewed by Healthlinks.net and accepted into its directory of select web sites. |
|
|
Privacy Policy Terms of Service
About FAQs
Copyright 2002-2008 Gelfar Ltd.
|
|
|
